CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price hit a new 52-week low during trading on Monday . The company traded as low as $36.70 and last traded at $37.04, with a volume of 992191 shares traded. The stock had previously closed at $39.69.
Analyst Ratings Changes
Several research firms recently weighed in on CRSP. Needham & Company LLC restated a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Chardan Capital restated a "buy" rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a research note on Monday, December 30th. JMP Securities reiterated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Bank of America reduced their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $78.38.
Read Our Latest Analysis on CRISPR Therapeutics
CRISPR Therapeutics Stock Down 2.1 %
The company has a market cap of $3.32 billion, a price-to-earnings ratio of -13.73 and a beta of 1.68. The company has a fifty day simple moving average of $46.17 and a two-hundred day simple moving average of $48.60.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the company earned ($1.41) earnings per share. On average, research analysts predict that CRISPR Therapeutics AG will post -5.13 EPS for the current year.
Insider Activity
In other news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.10% of the company's stock.
Institutional Investors Weigh In On CRISPR Therapeutics
A number of large investors have recently modified their holdings of CRSP. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics during the 2nd quarter valued at approximately $35,000. Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics during the 4th quarter valued at approximately $39,000. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics during the 3rd quarter valued at approximately $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the 3rd quarter valued at approximately $43,000. Finally, National Bank of Canada FI grew its stake in CRISPR Therapeutics by 35.0% during the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company's stock valued at $46,000 after purchasing an additional 220 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.
CRISPR Therapeutics Company Profile
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Further Reading
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
